Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
©2024 The Authors; Published by the American Association for Cancer Research..
Adding anti-programmed cell death protein 1 (anti-PD-1) to 5-fluorouracil (5-FU)/platinum improves survival in some advanced gastroesophageal adenocarcinomas (GEA). To understand the effects of chemotherapy and immunotherapy, we conducted a phase II first-line trial (n = 47) sequentially adding pembrolizumab to 5-FU/platinum in advanced GEA. Using serial biopsy of the primary tumor at baseline, after one cycle of 5-FU/platinum, and after the addition of pembrolizumab, we transcriptionally profiled 358,067 single cells to identify evolving multicellular tumor microenvironment (TME) networks. Chemotherapy induced early on-treatment multicellular hubs with tumor-reactive T-cell and M1-like macrophage interactions in slow progressors. Faster progression featured increased MUC5A and MSLN containing treatment resistance programs in tumor cells and M2-like macrophages with immunosuppressive stromal interactions. After pembrolizumab, we observed increased CD8 T-cell infiltration and development of an immunity hub involving tumor-reactive CXCL13 T-cell program and epithelial interferon-stimulated gene programs. Strategies to drive increases in antitumor immune hub formation could expand the portion of patients benefiting from anti-PD-1 approaches.
SIGNIFICANCE: The benefit of 5-FU/platinum with anti-PD-1 in first-line advanced gastric cancer is limited to patient subgroups. Using a trial with sequential anti-PD-1, we show coordinated induction of multicellular TME hubs informs the ability of anti-PD-1 to potentiate T cell-driven responses. Differential TME hub development highlights features that underlie clinical outcomes. This article is featured in Selected Articles from This Issue, p. 695.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancer discovery - 14(2024), 5 vom: 01. Mai, Seite 766-785 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
An, Minae [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 01.05.2024 Date Revised 03.05.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/2159-8290.CD-23-0857 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368085732 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368085732 | ||
| 003 | DE-627 | ||
| 005 | 20240503232300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240206s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2159-8290.CD-23-0857 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1396.xml |
| 035 | |a (DE-627)NLM368085732 | ||
| 035 | |a (NLM)38319303 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a An, Minae |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.05.2024 | ||
| 500 | |a Date Revised 03.05.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2024 The Authors; Published by the American Association for Cancer Research. | ||
| 520 | |a Adding anti-programmed cell death protein 1 (anti-PD-1) to 5-fluorouracil (5-FU)/platinum improves survival in some advanced gastroesophageal adenocarcinomas (GEA). To understand the effects of chemotherapy and immunotherapy, we conducted a phase II first-line trial (n = 47) sequentially adding pembrolizumab to 5-FU/platinum in advanced GEA. Using serial biopsy of the primary tumor at baseline, after one cycle of 5-FU/platinum, and after the addition of pembrolizumab, we transcriptionally profiled 358,067 single cells to identify evolving multicellular tumor microenvironment (TME) networks. Chemotherapy induced early on-treatment multicellular hubs with tumor-reactive T-cell and M1-like macrophage interactions in slow progressors. Faster progression featured increased MUC5A and MSLN containing treatment resistance programs in tumor cells and M2-like macrophages with immunosuppressive stromal interactions. After pembrolizumab, we observed increased CD8 T-cell infiltration and development of an immunity hub involving tumor-reactive CXCL13 T-cell program and epithelial interferon-stimulated gene programs. Strategies to drive increases in antitumor immune hub formation could expand the portion of patients benefiting from anti-PD-1 approaches | ||
| 520 | |a SIGNIFICANCE: The benefit of 5-FU/platinum with anti-PD-1 in first-line advanced gastric cancer is limited to patient subgroups. Using a trial with sequential anti-PD-1, we show coordinated induction of multicellular TME hubs informs the ability of anti-PD-1 to potentiate T cell-driven responses. Differential TME hub development highlights features that underlie clinical outcomes. This article is featured in Selected Articles from This Issue, p. 695 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Mehta, Arnav |e verfasserin |4 aut | |
| 700 | 1 | |a Min, Byung Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Heo, You Jeong |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Samuel J |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Milan |e verfasserin |4 aut | |
| 700 | 1 | |a Bi, Lynn |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hyuk |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Tae Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Song-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Jeonghyeon |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Ryan J |e verfasserin |4 aut | |
| 700 | 1 | |a Strickland, Matthew R |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Woong-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Won Ki |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Kyoung-Mee |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seung Tae |e verfasserin |4 aut | |
| 700 | 1 | |a Klempner, Samuel J |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jeeyun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer discovery |d 2011 |g 14(2024), 5 vom: 01. Mai, Seite 766-785 |w (DE-627)NLM215937023 |x 2159-8290 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:5 |g day:01 |g month:05 |g pages:766-785 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2159-8290.CD-23-0857 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 5 |b 01 |c 05 |h 766-785 | ||